Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/31251
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2023-02-28T11:13:04Z-
dc.date.available2023-02-28T11:13:04Z-
dc.date.issued2016-12-29-
dc.identifier.citationAyar, Y. vd. (2017). ''Clinical outcomes and survival in AA amyloidosis patients''. Revista Brasileira de Reumatologia, 57(6), 535-544.en_US
dc.identifier.issn0482-5004-
dc.identifier.urihttps://doi.org/10.1016/j.rbre.2017.02.002-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2255502117300111-
dc.identifier.urihttp://hdl.handle.net/11452/31251-
dc.description.abstractAim: Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis. Methods: A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results. Results: Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65 +/- 3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p = 0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p = 0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p = 0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3 +/- 16 months. Conclusion: Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.en_US
dc.description.abstractResumo Objetivo: A amiloidose AA é uma complicação rara de condições inflamatórias crônicas. A maior parte dos pacientes com amiloidose AA apresenta nefropatia, que leva à insuficiência renal e à morte. Estudaram-se as características clínicas e a sobrevida em pacientes com amiloidose AA. Métodos: Analisaram-se retrospectivamente 81 pacientes (51 homens, 30 mulheres) com amiloidose AA comprovada por biópsia renal. Os pacientes foram divididos em grupos de desfecho bom e ruim de acordo com os resultados de sobrevida. Resultados: A maior parte dos pacientes (55,6%) tinha proteinúria na faixa nefrótica no momento do diagnóstico. Os distúrbios subjacentes mais frequentes foram a febre familiar do Mediterrâneo (FFM, 21,2%) e a artrite reumatoide (10,6%) no grupo de desfecho bom e a malignidade (20%) no grupo de desfecho ruim. Somente a pressão arterial diastólica no grupo de desfecho bom e o nível de fósforo no grupo de desfecho ruim foram mais elevados. Os níveis séricos de creatinina aumentaram após o tratamento em ambos os grupos, enquanto a proteinúria diminuiu no grupo de desfecho bom. O aumento na creatinina sérica e a diminuição na TFGe do grupo de desfecho ruim foram mais significativos no grupo de desfecho bom. No momento do diagnóstico, 18,5% e 27,2% de todos os pacientes tinham doença renal crônica avançada (estágios 4 e 5, respectivamente). A duração média da sobrevida renal foi de 65 ± 3,54 meses. Entre todos os pacientes, 27,1% iniciaram tratamento de diálise durante o período de seguimento e 7,4% de todos os pacientes foram submetidos a transplante renal. Níveis elevados de pressão arterial sistólica [taxas de risco (HR) 1,03, intervalo de confiança (IC) de 95%: 1 a 1,06, p = 0,036], creatinina sérica (HR 1,25, IC 95%: 1,07 a 1,46, p = 0,006) e excreção urinária de proteínas (HR 1,08, IC 95%: 1,01 a 1,16, p = 0,027) foram preditores de doença renal terminal. A mediana da sobrevida de pacientes com comprometimento de órgãos foi de 50,3 ± 16 meses. Conclusão: O presente estudo indicou que a FFM constituiu uma grande proporção de casos e crescente quantidade de pacientes com amiloidose AA idiopática. Adicionalmente, observou-se que a sobrevida do paciente não foi afetada pelas diferentes causas etiológicas na amiloidose AA.fre
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectRheumatologyen_US
dc.subjectAA amyloidosisen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectFamilial mediterranean feveren_US
dc.subjectMortalityen_US
dc.subjectRenal survivalen_US
dc.subjectSystemic amyloidosisen_US
dc.subjectRenal involvementen_US
dc.subjectPrevalenceen_US
dc.subjectOriginen_US
dc.titleClinical outcomes and survival in AA amyloidosis patientsen_US
dc.title.alternativeDesfechos clínicos e sobrevida em pacientes com amiloidose AAfre
dc.typeArticleen_US
dc.identifier.wos000417146600006tr_TR
dc.identifier.scopus2-s2.0-85034596979tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.contributor.orcid0000-0003-4607-9220tr_TR
dc.contributor.orcid0000-0002-7846-0870tr_TR
dc.contributor.orcid0000-0003-4607-9220tr_TR
dc.identifier.startpage535tr_TR
dc.identifier.endpage544tr_TR
dc.identifier.volume57tr_TR
dc.identifier.issue6tr_TR
dc.relation.journalRevista Brasileira de Reumatologiaita
dc.contributor.buuauthorAyar, Yavuz-
dc.contributor.buuauthorErsoy, Alpaslan-
dc.contributor.buuauthorÖksüz, Mustafa Ferhat-
dc.contributor.buuauthorOcakoğlu, Gökhan-
dc.contributor.buuauthorVuruşkan, Berna Aytaç-
dc.contributor.buuauthorYıldız, Abdülmecit-
dc.contributor.buuauthorIşıktaş, Emel-
dc.contributor.buuauthorOruç, Ayşegül-
dc.contributor.buuauthorÇelikçi, Sedat-
dc.contributor.buuauthorArslan, İsmail-
dc.contributor.buuauthorŞahin, Ahmet Bilgehan-
dc.contributor.buuauthorGüllülü, Mustafa-
dc.contributor.researcheridAAH-5180-2021tr_TR
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.researcheridAAH-4002-2021tr_TR
dc.contributor.researcheridGSE-0029-2022tr_TR
dc.contributor.researcheridO-9948-2015tr_TR
dc.contributor.researcheridAAM-4927-2020tr_TR
dc.contributor.researcheridAAH-9746-2021tr_TR
dc.contributor.researcheridAGF-0767-2022tr_TR
dc.identifier.pubmed29173691tr_TR
dc.subject.wosRheumatologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.contributor.scopusid55860143300tr_TR
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid56016440100tr_TR
dc.contributor.scopusid15832295800tr_TR
dc.contributor.scopusid56527372000tr_TR
dc.contributor.scopusid56256977500tr_TR
dc.contributor.scopusid25654785700tr_TR
dc.contributor.scopusid55133912100tr_TR
dc.contributor.scopusid56497114200tr_TR
dc.contributor.scopusid7004617712tr_TR
dc.contributor.scopusid57188809248tr_TR
dc.contributor.scopusid6602684544tr_TR
dc.subject.scopusAL Amyloidosis; Cardiomyopathies; Melphalanen_US
dc.subject.emtreeAA amyloidosisen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChronic kidney failureen_US
dc.subject.emtreeClinical outcomeen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeDiastolic blood pressureen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeEnd stage renal diseaseen_US
dc.subject.emtreeEstimated glomerular filtration rateen_US
dc.subject.emtreeFamilial Mediterranean feveren_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHemodialysisen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeKidney transplantationen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeProteinuriaen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeRheumatoid arthritisen_US
dc.subject.emtreeSurvivalen_US
dc.subject.emtreeUrinary excretionen_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreePhosphorusen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Ayar_vd_2017.pdf744.29 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons